Halozyme Therapeutics (HALO) Inventory Average (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Inventory Average data on file, last reported at $166.0 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $166.0 million, up 8.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $166.0 million (up 8.22% YoY), and the FY2025 annual result was $159.2 million, up 18.14% from the prior year.
• Inventory Average declined to $166.0 million in Q1 2026 per HALO's latest filing, from $181.1 million in the prior quarter.
• Over five years, Inventory Average peaked at $183.7 million in Q3 2025 and troughed at $50.8 million in Q1 2022.
• A 5-year average of $132.9 million and a median of $136.6 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2022 and 2023: Inventory Average dropped 14.63% in 2022, then surged 104.24% in 2023.
• A 5-year view of Inventory Average shows it stood at $101.7 million in 2022, then rose by 26.12% to $128.3 million in 2023, then increased by 6.53% to $136.6 million in 2024, then soared by 32.57% to $181.1 million in 2025, then retreated by 8.37% to $166.0 million in 2026.
• Business Quant data shows HALO's Inventory Average at $166.0 million in Q1 2026, $181.1 million in Q4 2025, and $183.7 million in Q3 2025.